| Liu, Yu C |
NCT06216340: Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes |
|
|
| Not yet recruiting | 4 | 300 | NA | Henagliflozin, diet-exercise therapy, Placebo | The First People's Hospital of Changzhou, The Second Hospital of Nanjing Medical University, The First Affiliated Hospital of Soochow University, Second Affiliated Hospital of Soochow University, Wuxi People's Hospital, Northern Jiangsu People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Affiliated Hospital of Jiangsu University, The fourth affiliated hospital of nantong university | Obese, Weight Loss, Pre-diabetes | 10/26 | 10/26 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
| Not yet recruiting | 3 | 358 | RoW | TQB2450+Anlotinib, TQB2450 placebo + Anlotinib placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer Limited Stage | 09/26 | 09/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
| Recruiting | N/A | 150 | RoW | 99mTc-HFAPI | Peking Union Medical College Hospital | Pulmonary Fibrosis | 07/23 | 07/24 | | |
| Completed | N/A | 2071 | RoW | pancreatic extracorporeal shock wave lithotripsy | Changhai Hospital | Pancreatic Duct Stone | 04/24 | 05/24 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT06581653: Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy |
|
|
| Recruiting | N/A | 206 | RoW | Phone-based PERT education intervention | Changhai Hospital | Chronic Pancreatitis, Pancreatic Exocrine Insufficiency | 03/25 | 12/25 | | |
| Chen, Xiaolin |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
NCT06138353: Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS) |
|
|
| Recruiting | 2/3 | 50 | RoW | Shuxuening injection or placebo | Xiaolin Chen, MD | Subarachnoid Hemorrhage, Aneurysmal | 11/25 | 11/25 | | |
NCT04135456: The Optimal Dose of Mannitol for Intraoperative Brain Relaxation During the Operation of Aneurysmal Subarachnoid Hemorrhage |
|
|
| Active, not recruiting | 1/2 | 99 | RoW | Mannitol | Beijing Tiantan Hospital | Aneurysmal Subarachnoid Hemorrhage | 11/23 | 01/24 | | |
NCT04714489: Public Title：A Study on the Registration of The Use of Feilike HeJi in Adults |
|
|
| Recruiting | N/A | 3000 | RoW | NO. | China Academy of Chinese Medical Sciences | Bronchial Asthma | 06/21 | 08/21 | | |
| Recruiting | N/A | 10000 | RoW | Multimodal CT | Xiaolin Chen, MD, Peking University International Hospital, Zhangzhou Municipal Hospital of Fujian Province, The First Affiliated Hospital of Shanxi Medical University, Santai County People's Hospital, Jiujiang No.1 People's Hospital, Qin Zhou NO.1 People's Hospital | Acute Hemorrhagic Stroke | 03/32 | 04/32 | | |
| Recruiting | N/A | 5000 | RoW | Surgical clipping and endovascular coiling | Beijing Tiantan Hospital, Peking University International Hospital | Aneurysmal Subarachnoid Hemorrhage | 03/32 | 04/32 | | |
